tetano
Editor, Senior Moderator
Int Trends Immun. 2014 Apr 1;2(2):83-86.
Influenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III.
Smee DF1, Hurst BL1, Day CW1, Geiben-Lynn R2.
Author information
Abstract
Endogenous serine protease inhibitors (serpins) are anti-inflammatory mediators with multiple biologic functions. Serpins are also part of the early innate immune response to viral infection that includes mannose binding lectins, soluble CD14, defensins and antimicrobial peptides. Recently, serpin antithrombin III (ATIII) was shown to have broad-spectrum antiviral activity against HIV, HSV and HCV. We tested ATIII's antiviral activity against a variety of influenza virus strains. In our studies we found strong in vitro inhibition of influenza virus A H1N1 isolates. Our data also demonstrate that ATIII potency was more than 100-fold that of ribavirin. We also found that inhibition was dependent on viral hemagglutinin with decreasing efficacy in the order of H1N1 > H3N2 > H5N1 >> Flu B. In vivo efficacy is currently still lacking demonstrating need for more advanced delivery methods for this biomolecule. Understanding how ATIII regulates influenza virus inhibition may reveal new avenues for therapeutic interventions.
KEYWORDS:
Antithrombin III; Serpin; hemagglutinin dependent; influenza virus H1N1
PMID:
24883334
[PubMed]
http://www.ncbi.nlm.nih.gov/pubmed/24883334
Influenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III.
Smee DF1, Hurst BL1, Day CW1, Geiben-Lynn R2.
Author information
Abstract
Endogenous serine protease inhibitors (serpins) are anti-inflammatory mediators with multiple biologic functions. Serpins are also part of the early innate immune response to viral infection that includes mannose binding lectins, soluble CD14, defensins and antimicrobial peptides. Recently, serpin antithrombin III (ATIII) was shown to have broad-spectrum antiviral activity against HIV, HSV and HCV. We tested ATIII's antiviral activity against a variety of influenza virus strains. In our studies we found strong in vitro inhibition of influenza virus A H1N1 isolates. Our data also demonstrate that ATIII potency was more than 100-fold that of ribavirin. We also found that inhibition was dependent on viral hemagglutinin with decreasing efficacy in the order of H1N1 > H3N2 > H5N1 >> Flu B. In vivo efficacy is currently still lacking demonstrating need for more advanced delivery methods for this biomolecule. Understanding how ATIII regulates influenza virus inhibition may reveal new avenues for therapeutic interventions.
KEYWORDS:
Antithrombin III; Serpin; hemagglutinin dependent; influenza virus H1N1
PMID:
24883334
[PubMed]
http://www.ncbi.nlm.nih.gov/pubmed/24883334